Biosimilars

September 30, 2020

September 28, 2020

The Alliance of Community Health Plans calls for changes to get more biosimilars approved and on the market.

September 28, 2020

Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.

August 18, 2020

Authors of a review say biosimilars would improve treatment, not just reduce cost.

August 17, 2020

Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.

August 05, 2020

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.

July 30, 2020

Advocates say a number of regulatory changes could help bring more of these products on to the market.

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

July 09, 2020

Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.

July 08, 2020

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.